Locatelli F, Pedrazzoli P, Zecca M, Maccario R, Giorgiani G, Prete L, Nespoli L, Severi F
Clinica Pediatrica, Università, IRCCS Policlinico S. Matteo, Pavia, Italy.
Haematologica. 1991 May-Jun;76(3):238-9.
We describe the case of a 12-year-old boy affected by cyclic neutropenia, at high risk of developing life-threatening infections, treated with recombinant human granulocyte-macrophage colony stimulating factor (rHuGM-CSF). The drug was effective in reducing the severity of neutropenia and infectious complications in our patient. It was administered for brief periods of time, in contrast to the daily continuous administration reported for rHuG-CSF. Therefore, more extensive studies must be performed to identify the most effective time schedule for the drug. In vitro studies of hemopoietic progenitor cells were useful, in this case, to predict treatment response.
我们描述了一名12岁患周期性中性粒细胞减少症男孩的病例，该男孩有发生危及生命感染的高风险，接受了重组人粒细胞巨噬细胞集落刺激因子（rHuGM-CSF）治疗。该药物在降低我们患者中性粒细胞减少的严重程度和感染并发症方面有效。与报道的rHuG-CSF每日持续给药不同，它是短期给药。因此，必须进行更广泛的研究以确定该药物最有效的给药方案。在这种情况下，造血祖细胞的体外研究有助于预测治疗反应。
